Soligenix (SNGX) closed at $0.36 on October 27, 2026, up 3.7% from the previous close, on volume of 68,727 shares (30-day average 194,635).
Data as of October 27, 2026.
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
PRNewswire (Fri, 7-Aug 7:31 AM ET)
Soligenix's Thermostable Vaccine Platform Shows Promise for Bundibugyo Virus Amid Ongoing Outbreak
Market Chameleon (Wed, 27-May 5:52 AM ET)
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Soligenix trades on the NASDAQ stock market under the symbol SNGX.
As of October 27, 2026, SNGX stock price climbed to $0.36 with 68,727 million shares trading.
SNGX has a beta of 1.97, meaning it tends to be more sensitive to market movements. SNGX has a correlation of 0.02 to the broad based SPY ETF.
SNGX has a market cap of $7.90 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, SNGX traded as high as $32.00 and as low as $.28.
The top ETF exchange traded funds that SNGX belongs to (by Net Assets): VXF.
SNGX has underperformed the market in the last year with a return of -77.0%, while the SPY ETF gained +14.8%. In the last 3 month period, SNGX fell short of the market, returning -2.2%, while SPY returned +4.4%. However, in the most recent 2 weeks SNGX has outperformed the stock market by returning +3.2%, while SPY returned -1.1%.
SNGX support price is $.34 and resistance is $.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNGX shares will trade within this expected range on the day.
